Stay updated on Pembrolizumab with Radium-223 in mCRPC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page.

Latest updates to the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check11 days agoChange DetectedThe ClinicalTrials.gov record for the completed study of pembrolizumab plus radium-223 for metastatic castration-resistant prostate cancer is displayed, including its study design, eligibility criteria, outcomes, and investigator information.SummaryDifference57%

- Check18 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedA sitewide NIH notice about terminology changes appears above the page, and the site revision updates from v3.7.1 to v3.7.2.SummaryDifference1%

- Check46 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange DetectedAccess to the study record returns a 403 Forbidden page instead of the study details, preventing viewing the trial information. The page displays a 403 message with a Home button, indicating restricted access to the content.SummaryDifference20%

Stay in the know with updates to Pembrolizumab with Radium-223 in mCRPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Radium-223 in mCRPC Clinical Trial page.